Candel Therapeutics

Updated data from the phase 2 clinical trial of CAN-2409 in non-small cell lung cancer showing disease control rate of 77 percent in patients entering the study with progressive disease, translating into preliminary evidence of improved…

Disease control rate of 87.5 percent achieved in patients who were all progressing on anti-PD-1 therapy at trial entryDurable disease stabilization that was ongoing at data cutoff in 62.5 percent of the patients who entered the study with…

NEEDHAM, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that an abstract has been…

Partnership for Accelerating Cancer Therapies to conduct extensive biomarker analysis for ongoing phase 2 clinical trial in non-small cell lung cancerTrial combines CAN-2409 with immune checkpoint inhibitor treatment after inadequate tumor…

Data presented at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual MeetingIntra-tumoral administration of CAN-3110 elicited significant T-cell infiltration and expansion of T-cell repertoire in patients with recurrent…

NEEDHAM, Mass., Oct. 04, 2021 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Nasdaq: CADL), a late clinical stage biopharmaceutical company developing novel oncolytic viral immunotherapies, today announced that the Company will present…